Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib (HM43239) for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events

Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

May 12, 2022 10:00am EDT

Aptose Reports Results for the First Quarter 2022

May 09, 2022 4:01pm EDT

Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation

May 04, 2022 7:30am EDT

Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference

May 03, 2022 7:30am EDT

Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation

May 02, 2022 4:10pm EDT

Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022

Apr 25, 2022 7:30am EDT

Aptose Announces Executive Management Changes

Apr 07, 2022 7:00am EDT

Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference

Mar 31, 2022 7:30am EDT

Aptose Reports Results for the Fourth Quarter and Full Year 2021

Mar 22, 2022 4:01pm EDT

Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022

Mar 08, 2022 7:30am EST
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...25
    Next
    © 2023 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap